Skip to Content

Duexis Approval History

Duexis (ibuprofen and famotidine) is an NSAID and histamine H2-receptor antagonist combination indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper GI ulcers.

Development History and FDA Approval Process for Duexis

Apr 25, 2011Approval Horizon Pharma Announces FDA Approval of Duexis (Ibuprofen/Famotidine)
May 26, 2010Horizon Pharma, Inc. Announces FDA Acceptance of Duexa New Drug Application for Filing

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.